SAN DIEGO, March 3, 2015 /PRNewswire/ -- MabVax Therapeutics (OTCQB: MBVX), a cancer diagnostic and immunotherapy company, announced today that David Hansen, the Company’s President and CEO, will be presenting at the 27th Annual Roth Conference to be held March 9 12, 2015 at the Ritz Carlton in Laguna Niguel, California.
MabVax’s presentation is scheduled for Wednesday, March 11th, at 11:30 AM Pacific Time. The presentation will be available for review on the Investor Relations section of the Company’s website at www.mabvax.com.
About MabVax
MabVax Therapeutics Holdings, Inc. is cancer diagnostic and immunotherapy company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines. The Company’s lead antibody candidate HuMab 5B1 is being developed as both a diagnostic product and therapeutic agent for the diagnosis and treatment of GI cancers and specifically pancreatic cancer. The antibody product is scheduled to enter Phase I clinical trials later this year. MabVax has the exclusive license to a portfolio of therapeutic vaccines from Memorial Sloan Kettering Cancer Center. The Company has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and plans to have a third vaccine targeting neuroblastoma ready for Phase II clinical development later this year.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-to-present-at-the-27th-annual-roth-conference-300043898.html
SOURCE MabVax Therapeutics
Help employers find you! Check out all the jobs and post your resume.
